Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT06909825 is registered in ClinicalTrials.gov with Fusion Pharmaceuticals Inc. as lead sponsor.

NCT NCT06909825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06909825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lead sponsor
Fusion Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 26, 2025
Completion date
May 31, 2027
Enrollment
85 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer